The EPS projection of Seattle Genetics, Inc. (NASDAQ:SGEN) for period quarter completed 2016-12-31 is $-0.32.
The EPS estimates pronounced a week and 30 days ago were $-0.32 and $-0.32 correspondingly. The EPS forecasts specified 60 and 90 days before were $-0.32 and $-0.32 respectively. From a week ago, the aberration in EPS forecast is 0 percent.
The mean EPS prediction straightaway before the earnings release for the quarter completed 2 is $-0.32 based on 8 EPS estimations. The EPS stated on 2016-07-26 was $-0.23. The EPS surprise was $0.1, or 30.3 percent. The standard deviation as per known EPS estimates was $0.03.
The positive EPS revisions were 0 a week earlier and negative revisions were 0. In last 30 and 60 days, the positive EPS revisions were 0 and 0 correspondingly, while for 90 and 120 days, revisions count was 2 and 2.
The negative revisions of per-share earnings in the last 30 and 60-days were 0 and 0 in that order. however, for 90 and 120 days’ period, the count was 3 and 3 in that order.
EPS revisions upgrade and downgrade in the last 18 days were 2 and 3 correspondingly.
Quarterly Sales Estimates
The arithmetic mean of probable annual sales of Seattle Genetics, Inc. (NASDAQ:SGEN) is $108.318 and the median was $106.3. The estimate is stated by 5 analysts for the fiscal 2016.
The highest annual projection is $115.21 and lowest sales target is $103.802. This marks a standard deviation of $4.442.
Almost 5 have given revised positive sales forecast in the past week and 5 have downgraded forecasts. As per the stated estimates, the change in target from the past week is 1.616 percent.
Nearly 5 have revised sales projections in positive side over the past month and 5 have downgraded forecasts. This shows a mean estimate deviation of 1.312 percent.
Just about 5 have revised sales forecast on plus side over the quarter and 5 have downgraded forecasts. This shows mean estimate deviation of -0.238 percent.
1 Chart Pattern Every Investor Should Know